AIDS TREATMENT NEWS No. 053 - March 25, 1988
John S. James
The oral testimony, on the fourth of six recommendations to the Commission, was as follows:
"I believe in greatly accelerated clinical trials. When you look at our projections to 1993 you can see that the clock is ticking. The current national cooperative drug trial system is cumbersome and unduly long; it just won't produce the results fast enough.
"And there are other approaches. We could do community-based trials in high-prevalence areas. We'd be perfectly happy to do it here in San Francisco under Health Department auspices. We can get clinical trials, large scale, with controls, going tomorrow. The current clinical trials, I'm afraid, are just leaden-footed."
The prepared text reads as follows:
"Greatly accelerated clinical trials of potentially useful drugs to reduce the morbidity and mortality of HIV infection. The national cooperative drug trial approach is unduly long and cumbersome. It should be supplemented by speedier mechanisms. As our own projections show only too well, time is of the essence.
"Community-based trials in high prevalence areas is one such approach. The Health Department in San Francisco, for example, would welcome the opportunity to conduct large scale clinical trials locally, utilizing the San Francisco General Hospital, the Public Health Hospital, community hospitals and practitioners, and the University of California Health Science Center. These could get under way promptly."
The other five recommendations concerned a comprehensive national plan; Federal block grants for education, prevention, and treatment, directly to the health departments of cities seriously affected by the AIDS epidemic; financial incentives for the development and support of long-term care services; continued support of anonymous and confidential testing programs; and legislation to prevent discrimination in jobs, housing, and health insurance.
We find the research recommendation particularly noteworthy, as it is one of the very few times that any government official has broken with the official line that we're moving as fast as we can, Science can't be rushed, there is no faster way--and too bad about those now infected.
Dr. Werdegar's statement also hints that the central issue in treatment research is NOT financial. What we need most-- quick, practical trials which could be integrated with ongoing patient care--would cost relatively little, much less than the ineffectual research programs now in place, and far, far less than the cost of care of perhaps hundreds of thousands of cases of unnecessary terminal illness.
880325
ATN05301
Copyright © 1988 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .